Israel Active

Ofer Shalev, Founder & CEO at Israel’s New Phase (see previously) spoke at CTech’s Mind the Tech NY Conference.  New Phase’s hyperthermic therapy reduces cancer from Stage 4 to Stage 2 so patients can live with a better quality of life. Clinical trials have started.  

Professors from the Hebrew University of Jerusalem and the Hadassah Cancer Research Institute are leading CanceRNA - a European consortium working to develop novel immunotherapy treatments for cancer. The consortium will initially focus on treating acute myeloid leukemia.

Scientists at Israel’s Weizmann Institute have developed a blood test to detect colorectal cancer, which is normally found through an invasive test, and pancreatic cancer, which has no single diagnostic test. The proof of concept is now to be taken to trials.

Israel’s Oramed (see previously) has reported that its ORMD-0801 oral insulin candidate successfully reduced the liver fat in its Phase 2 trial on Type 2 diabetes patients with non-alcoholic steatohepatitis ("NASH").  There were no safety issues in the double-blind, multi-center trial.

Israel’s 6Degrees (see previously) has made significant progress with its MyMove wristband that allows people who can’t use their hands to operate any phone, laptop, or tablet. It includes having Tel Aviv municipality adopt the wristband to help people with disabilities come back to work.

Israeli-US startup Hour25.ai has developed an app that learns and monitors a user’s activity patterns and gives an alert whenever it detects inactivity, fatigue or distraction. It then suggests a personalized intervention, e.g., take a walk, or perform an optional exercise.

A Haifa University-led team of international scientists has discovered a method to identify early Parkinson’s Disease cases. Brain cells of PD patients die when they disconnect from the extracellular matrix. Early detection and subsequent treatment could halt this process.

Israel has taken delivery of second-generation coronavirus vaccines, updated to better battle new variants. They are expected to be in clinics by the end of September. The international scientific community is again looking to see how well these new vaccines protect Israelis.

The Israel Cancer Research Fund (ICRF) has awarded 83 cancer research grants (28 new and 55 continuing) worth almost $5 million for the 2022-2023 funding year. ICRF’s funding has now reached 2,730 grants totaling more than $87.5 million.

Israel’s Ibex Medical Analytics (see previously) has launched a new cancer detection platform - Galen 3.0 with improved AI algorithms to detect cancer in prostate, breast and gastric biopsies. It also calculates the aggressiveness of prostate cancer, reducing time and errors.